(833) 317-6278
Book a Demo
Robin Foster
Gray shield icon
Is this you?
Claim your profile.

Robin Foster

Reporter And Editor

AS SEEN ON
HealthDay News, Newsmax Media, Inc., Medical Xpress, The Herald-Sun (Durham, NC), xpresschronicle.com

Preston's Summary

Robin Foster is a Reporter And Editor at HealthDay. With over 30 years of experience in journalism, she specializes in health and wellness, covering topics such as the coronavirus, FDA, CDC, and various social issues. Robin's work has been featured in numerous publications, including Phys.org, The Anniston Star, and the St. Louis Post-Dispatch.

Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston

Geo Focus

United States (National)

Coverage Attributes:

Beta
Cites Data: 46 %
Press Release: 20 %
Government Announcement: 20 %
Breaking News: 4 %
Seasonal: 2 %

Themes Covered:

Not enough data icon

Not enough data

Most Recent Topics:

  • Consumer Health
  • Drugs & Medication
  • Health News
  • Mental Health
  • Diet & Nutrition
  • Oncology

Pitching Insights

Robin's coverage focuses on healthcare and pharmaceuticals, with an emphasis on data-driven reporting, government announcements, and press releases. Sources who can provide scientific evidence or data to support their claims would likely be well received.

Given the variety of health topics covered, experts in fields such as medicine, public health, pharmacology, and related disciplines could find opportunities for commentary. Pitching relevant stories that align with Robin's focus on current issues in healthcare and pharmaceuticals may increase the likelihood of engagement.

As there is no specified geographic focus for Robin's articles, she appears to cover a wide range of global health-related topics without specific regional constraints.

This information evolves through artificial intelligence and human feedback. Improve this profile .

Journalists With Similar Coverage:

Based on similarity of content.
Dennis Thompson

Dennis Thompson

Health And Fitness Reporter
*****s@**********com
Publications
HealthDay News, Newsmax Media, Inc., Medical Xpress, RamaOnHealthcare, xpresschronicle.com
Most recent topics
Not enough data
Lindsey Theis

Lindsey Theis

Health And Wellness Reporter
*****s@*******om
Publications
Scripps News, KZTV 10 (CBS), WXYZ-TV, KOAA5, KJRH
Most recent topics
Not enough data
Merdie Nzanga

Merdie Nzanga

Frances Ellen Watkins Harper Reporting Fellow
**********nga@****************.com
Publications
The 19th
Most recent topics
Not enough data
Ernie Mundell

Ernie Mundell

Executive Editor, Consumer News Division
*******ll@**********com
Publications
HealthDay News, Newsmax Media, Inc., Medical Xpress, The Fresno Bee, SAMMY A. CAVES, D.M.D., P.C.
Most recent topics
Not enough data
Pandora Dewan

Pandora Dewan

Science Reporter
******n@**********om
Publications
Newsweek, Live Science
Most recent topics
Not enough data
Carole Tanzer Miller

Carole Tanzer Miller

Publications
HealthDay News, Newsmax Media, Inc., Medical Xpress, United Press International, RamaOnHealthcare
Most recent topics
Not enough data

Articles

HealthDay News

U.S. Teen Drug, Alcohol Use Remains at Low Levels

U.S. Teen Drug, Alcohol Use Remains at Low Levels

By: Ernie Mundell, Glp Meds Rose, Robin Foster, Carole Tanzer Miller

WEDNESDAY, Dec. 18, 2024 (HealthDay News) -- Rates of vaping, drug and alcohol use among American teens plummeted during the pandemic and have remained at relatively low levels ever since, new government statistics show.

HealthDay News

FDA Says Shortage of GLP-1 Tirzepatide Is Over

FDA Says Shortage of GLP-1 Tirzepatide Is Over

By: Ernie Mundell, Zepbound, Robin Foster, Zepbound, Dennis Thompson, Glp Meds, Lori Saxena

THURSDAY, Dec. 19, 2024 (HealthDay News) -- The U.S. Food and Drug Administration re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss med tirzepatide is over.

HealthDay News

GLP-1 Zepbound Is Approved As First Drug For Sleep Apnea

GLP-1 Zepbound Is Approved As First Drug For Sleep Apnea

By: Edwards, Glp Tirzepatide, Robin Foster, Zepbound, Lori Solomon, Zepbound, Dennis Thompson

MONDAY, Dec. 23, 2024 (HealthDay News) -- The U.S. Food and Drug Administration (FDA) has approved the first prescription medication specifically for treating obstructive sleep apnea (OSA): the weight-loss drug Zepbound.

© 2024 Intelligent Relations